ABSTRACT:
A new UPLC-MS/MS method has been developed for the simultaneous estimation of Rilpivirine and Cabotegravir in rabbit plasma and the method was validated. Cabotegravir and Rilpivirine are anti-viral drugs. The combination of Cabotegravir and Rilpivirine is used to inhibit the reproduction of the HIV-1 virus and it is available as long-acting injectable formulation. Agilent Eclipse Phenyl XDB column was employed for the study and a mixture of Acetonitrile and 2 mM Ammonium formate with 0.1% formic acid (40: 60) was used as mobile phase with flow rate 0.8 mL/min.
Cite this article:
Asia, Revu Baby Nalanda, Method development and validation for the simultaneous quantification of Rilpivirine and Cabotegravir in rabbit plasma using UPLC-MS/MS. Research Journal of Pharmacy and Technology. 2025;18(1):355-0. doi: 10.52711/0974-360X.2025.00055
Cite(Electronic):
Asia, Revu Baby Nalanda, Method development and validation for the simultaneous quantification of Rilpivirine and Cabotegravir in rabbit plasma using UPLC-MS/MS. Research Journal of Pharmacy and Technology. 2025;18(1):355-0. doi: 10.52711/0974-360X.2025.00055 Available on: https://rjptonline.org/AbstractView.aspx?PID=2025-18-1-55
REFERENCES:
1. Ripamonti D, Bombana E and Rizzi M. Rilpivirine: Drug profile of a second-generation non-nucleoside reverse transcriptase HIV-inhibitor. Expert Review of Anti-infective Therapy. 2014; 12(1): 13-29.
2. Yenda Manishankar and Mathrusri Annapurna M. Analytical techniques for the determination of Rilpivirine - A review. Acta Scientific Pharmaceutical Sciences. 2021; 5(1): 36-38.
3. McPherson TD, Sobieszczyk ME and Markowitz M. Cabotegravir in the treatment and prevention of Human Immunodeficiency Virus-1. Expert Opin Investig Drugs. 2018; 27: 413-420.
4. Orkin C, Arasteh, Górgolas Hernández-Mora M, Pokrovsky V, Overton ET, Girard PM, Oka S. Walmsley S, Bettacchi C, Brinson C and Philibert P. Long-acting Cabotegravir and Rilpivirine after oral induction for HIV-1 infection. New England Journal of Medicine. 2020; 382(12):1124-1135.
5. Haser GC, Balter L, Gurley S, Thomas M, Murphy T, Sumitani J, Leue EP, Hollman A, Karneh M, Wray L, Washington M, Corbin-Johnson D, Condra A, Niles-Carnes L, Smith BL, Armstrong WS, Kalokhe AS, Colasanti JA, Collins LF. Early Implementation and Outcomes Among People with HIV Who Accessed Long-Acting Injectable Cabotegravir/Rilpivirine at Two Ryan White Clinics in the U.S. South. AIDS Res Hum Retroviruses. 2024; 40(12): 690-700.
6. Ghosh S, Bomma S, Prasanna VL, Vidyadhar S, Banji D and Roy S. Method development and validation of Rilpivirine in bulk and tablet doses form by RP-HPLC method. Research Journal of Pharmacy and Technology. 2013; 6(3): 240-243.
7. Priyanka Vallabh Deulkar and Mukthinuthalapati Mathrusri Annapurna. A New stability indicating RP-UFLC method for the estimation of Rilpivirine in pharmaceutical dosage forms. Research Journal of Pharmacy and Technology. 2023; 16(7): 3456-3462.
8. Date AA, Shibata A, Bruck P and Destache CJ. Development and validation of a simple and isocratic reversed‐phase HPLC method for the determination of Rilpivirine from tablets, nanoparticles and HeLa cell lysates. Biomedical Chromatography. 2015; 29(5):709-715.
9. Shibata M, Takahashi M, Yoshino M, Kuwahara T, Nomura T, Yokomaku Y and Sugiura W. Development and application of a simple LC-MS method for the determination of plasma Rilpivirine (TMC-278) concentrations. The Journal of Medical Investigation. 2013; 60(1.2): 35-40.
10. Gupta A, Guttikar S, Patel Y, Shrivastav PS and Sanyal M. Reliable LC‐MS/MS assay for the estimation of Rilpivirine in human plasma: application to a bioequivalence study and incurred sample reanalysis. Drug Testing and Analysis. 2015; 7(4): 290-299.
11. Ramöller IK, Abbate MT, Vora LK, Hutton AR, Peng K, Volpe-Zanutto F, Tekko IA, Moffatt K, Paredes AJ, McCarthy HO and Donnelly RF. HPLC-MS method for simultaneous quantification of the antiretroviral agents Rilpivirine and cabotegravir in rat plasma and tissues. Journal of Pharmaceutical and Biomedical Analysis, 2022; 213: 114698.
12. Bioanalytical Method Validation Guidance for Industry, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine (CVM). 2018.